- Home
- IMCR vs PZZA Comparison
IMCR vs PZZA Comparison
Compare IMCR & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- PZZA
- Stock Information
- Founded
- IMCR 2008
- PZZA 1984
- Country
- IMCR United Kingdom
- PZZA United States
- Employees
- IMCR N/A
- PZZA N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- PZZA Restaurants
- Sector
- IMCR Health Care
- PZZA Consumer Discretionary
- Exchange
- IMCR Nasdaq
- PZZA Nasdaq
- Market Cap
- IMCR 1.7B
- PZZA 1.5B
- IPO Year
- IMCR 2021
- PZZA 1993
- Fundamental
- Price
- IMCR $33.50
- PZZA $50.83
- Analyst Decision
- IMCR Buy
- PZZA Buy
- Analyst Count
- IMCR 9
- PZZA 10
- Target Price
- IMCR $62.38
- PZZA $50.00
- AVG Volume (30 Days)
- IMCR 350.0K
- PZZA 1.7M
- Earning Date
- IMCR 11-06-2025
- PZZA 11-06-2025
- Dividend Yield
- IMCR N/A
- PZZA 3.33%
- EPS Growth
- IMCR N/A
- PZZA 8.47
- EPS
- IMCR N/A
- PZZA 2.28
- Revenue
- IMCR $356,145,000.00
- PZZA $2,085,052,000.00
- Revenue This Year
- IMCR $29.99
- PZZA $4.55
- Revenue Next Year
- IMCR $8.85
- PZZA $0.93
- P/E Ratio
- IMCR N/A
- PZZA $22.64
- Revenue Growth
- IMCR 26.78
- PZZA N/A
- 52 Week Low
- IMCR $23.15
- PZZA $30.16
- 52 Week High
- IMCR $39.33
- PZZA $60.75
- Technical
- Relative Strength Index (RSI)
- IMCR 49.73
- PZZA 53.49
- Support Level
- IMCR $31.36
- PZZA $51.83
- Resistance Level
- IMCR $34.18
- PZZA $55.74
- Average True Range (ATR)
- IMCR 1.38
- PZZA 2.53
- MACD
- IMCR -0.00
- PZZA 0.26
- Stochastic Oscillator
- IMCR 60.51
- PZZA 65.50
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.